Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2019-07-15 Director's Dealing
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
108年06月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司, including directors, managers, and major shareholders. It lists the number of shares held, pledged shares, and related percentages. There is no indication of financial statements, earnings data, or management discussion. The document is not a report but a disclosure of insider shareholdings and pledges, which aligns with insider or director dealings. Given the content focuses on shareholdings by directors and executives, it fits the category of Director's Dealing (DIRS). The document length is 3148 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement. Therefore, the classification is DIRS with high confidence.
2019-07-15 Chinese
108年06月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and stock ownership information of company insiders, including directors, managers, and their related parties. It includes data on shares held, increases, decreases, and trust shares. The content is focused on insider shareholdings and changes thereof. There is no indication of financial statements, earnings data, meeting materials, or legal proceedings. The document is a notification of insider shareholdings and transactions by directors and executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is sufficient and contains substantive data, not just an announcement or certification.
2019-07-15 Chinese
108年6月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, providing information about the absence of fund loans and endorsement guarantees for the current and previous months, with amounts stated as zero. It contains no detailed financial statements, no management discussion, no audit information, and no regulatory or legal updates. The document is very short (601 characters) and appears to be a routine regulatory disclosure of financial status related to loans and guarantees. It does not fit into detailed report categories like Annual Report, Interim Report, or Earnings Release. It is not an announcement of a report publication either. Given the nature and brevity, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2019-07-09 Chinese
108年6月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a summary revenue report for a company named 旭富 for the period 民國108年06月 (June 2019). It contains monthly and cumulative net operating revenue figures with comparisons to the previous year. The document is very short (771 characters) and appears to be a financial summary or factsheet rather than a full financial report. There is no indication of detailed financial statements, management discussion, or regulatory certifications. It is not an announcement of a report but a brief summary of key financial data. This matches the description of a Fund Information / Factsheet (FS) which is a brief summary of key company facts and financials.
2019-07-09 Chinese
108年年報及股東會資料 — 2019_4119_20190621F05.pdf
AGM Information Classification · 95% confidence The document is a detailed record of an Annual General Meeting (AGM) of a company, including attendance, reports on employee and director remuneration, business reports for the fiscal year 107 (which corresponds to 2018 in the Gregorian calendar), audit committee reports, election of directors, discussions on amendments to company procedures, and dividend distribution proposals. It contains voting results and resolutions passed during the meeting. The presence of detailed meeting minutes, voting results, and discussions on company governance and financial matters strongly indicate this is an AGM Information document. The document is lengthy (15,000 characters) and contains substantive content from the meeting itself, not just an announcement or summary. Therefore, it fits the category of AGM Information (AGM-R).
2019-07-05 Chinese
108年年報及股東會資料 — 2019_4119_20190621F14.pdf
Governance Information Classification · 95% confidence The document is a detailed procedural manual titled '取得或處分資產處理程序' (Procedures for Acquisition or Disposal of Assets) issued by a company named 旭富製藥科技股份有限公司. It references regulatory requirements from the Financial Supervisory Commission (金管會) and covers comprehensive internal control procedures, authorization levels, evaluation methods, and reporting requirements related to asset acquisition and disposal, including securities, real estate, equipment, intangible assets, derivatives, and mergers and acquisitions. The document includes detailed governance and compliance rules, risk management, and disclosure obligations. It is not a financial report, earnings release, or announcement but a governance and procedural document outlining internal rules and practices for asset transactions and related corporate actions. Therefore, it fits best under Governance Information (CGR). The document length (over 14,000 characters) and content confirm it is a full procedural guideline, not a brief announcement or certification.
2019-07-05 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.